# Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring

> **NCT04460781** · — · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 96175 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Flublok Quadrivalent influenza vaccine RIV4
- **BIOLOGICAL:** Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4

## Key facts

- **NCT ID:** NCT04460781
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-17
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 96175 (ACTUAL)
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04460781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04460781, "Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04460781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*